法国儿童中阿片类药物和尼福帕姆使用趋势:2009年至2023年的基于人口的研究
Sandrella Hamdan1,2,3, Pierre Pinson1, Jean-Marc Tréluyer1,4,5,6
1UMRS 1343 INSERM, Perinatal and Pediatric Pharmacology and Therapeutic Assessment, Université Paris Cité, Paris, France.
Clinical drug investigation
|November 3, 2025
概括
法国儿童中阿片类药物和内福帕姆的使用增加,其中特拉马多尔和可代因是最常见的. 非标签处方,特别是幼儿特拉马多尔的处方增加,突出了安全问题.
科学领域:
- 儿科药理学 儿科药理学
- 公共卫生 公共卫生
- 药物使用研究研究药物使用研究.
背景情况:
- 儿童有效的疼痛管理至关重要,但阿片类药物风险是一个重大问题.
- 了解儿科止痛药处方趋势对于患者安全至关重要.
研究的目的:
- 描述2009年至2023年法国儿童使用阿片类药物和内福帕姆的趋势.
- 为了确定非标签处方和与年龄相关的使用模式.
主要方法:
- 使用法国国家健康数据系统 (SNDS) 进行全国范围的药物使用研究.
- 包括所有处方为弱阿片类药物,强阿片类药物或内福帕姆 (2009-2023) 的儿童.
- 分析年度流行率和时间趋势,使用结点回归,按年龄组分层.
主要成果:
- 总体而言,止痛药的使用量从22.7‰增加到27.4‰,主要是由于弱阿片类药物,如特拉马多尔和可代因.
- 尼福帕姆的使用量显著增加,尽管在15岁以下的儿童中存在禁忌.
- 在2-6岁的儿童中,特拉马多尔的使用量增加了8倍,经常开出非标签的多种止痛药处方.
结论:
- 特拉马多尔是法国儿科门诊患者处方最多的阿片类药物,越来越多的非标签使用,特别是在年幼的儿童中.
- 特拉马多尔和内福帕姆使用的增加,以及强烈的阿片类药物处方的增加,需要加强监测.
- 迫切需要儿科特异性安全数据和对儿童止痛药处方的严格监测.
相关概念视频
Prescription, Nonprescription and Orphan Drugs
1.2K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.2K
Opioid Analgesics: Synthetic and Semisynthetic Opioids
906
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
906
Opioid Analgesics: Morphine and Other Natural Cogeners
837
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
837
Pharmacokinetics in Pediatric Patients: Drug Excretion
201
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
201
Pharmacokinetics in Pediatric Patients: Drug Metabolism
185
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
185
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
239
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
239


